



The Leerink Partners 7th Annual Global Healthcare Conference

Paolo Pucci, Chief Executive Officer

Dr. Brian Schwartz, M.D., Head of Research and
Development and Chief Medical Officer

February 15, 2018



This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act including, without limitation, statement with respect to current and proposed clinical trials with the Company's product candidates derazantinib (ARQ 087), miransertib (ARQ 092), ARQ 751, ARQ 761 and ARQ 531, financial operations and results, corporate partnerships and future business objectives, goals, opportunities and strategies. Forward-looking statements are typically identified by words such as "believe," "expect," "anticipate," "intend," "outlook," "position" and similar expressions, or future or conditional verbs such as "will," "should," "would," and "could." Forward-looking statements are subject to numerous assumptions, risks and uncertainties. Forward-looking statements speak only as of today, and ArQule assumes no obligation to update them. Actual results may differ materially from forward-looking statements or historical performance due to the factors discussed in this presentation and factors previously disclosed in ArQule's SEC reports. See discussion of Risk Factors in the Company's Annual Report on Form 10-K as filed with the SEC. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. ArQule's product candidates are in various stages of development and are not available for sale or use outside of approved clinical trials.

ArQule and the ArQule logo are registered trademarks of ArQule, Inc.

The ArQule Clinical Strategy



To efficiently develop a proprietary clinical pipeline in oncology and rare diseases with near-term inflection points offering fast-to-market opportunities

Hematological B-cell malignancies where resistance is driven by C481S mutation

ARQ 531
BTK Inhibitor

Rare Overgrowth Diseases and Proteus syndrome

Miransertib (ARQ 092)
AKT Inhibitor

Intrahepatic Cholangiocarcinoma
FGFR2 Fusions

Derazantinib (ARQ 087)
FGFR Inhibitor

- Cash Balance
 - Cash and marketable securities at September 30, 2017 \$37.6 Mil
- 2017 Guidance
 - Net use of cash \$25-27 Mil
 - Projected cash balance end of 2017* \$47-49 Mil
- Shares Outstanding at September 30, 2017* ~87.1 Mil

*Reflects updated guidance as of November 9, 2017 which includes ~\$15.5M in net proceeds from a private placement of common stock in October 2017, ~\$4M from unrelated business development activities and other sources during September and October of 2017, and \$9.3M in net proceeds from a private placement of convertible preferred stock on November 2017.

Clinical Development Outlook



COMPOUND	TARGET	CURRENT STAGE	TARGET FOR NEXT STAGE	INDICATION
ARQ 531	BTK	Phase 1a/b	Registrational	Heme malignancies
Miransertib (ARQ 092)	AKT	Phase 1/2	Registrational	Proteus syndrome - PROS
Derazantinib (ARQ 087)	FGFR	Registrational	Conditional Approval	iCCA (Intrahepatic Cholangiocarcinoma)
ARQ 751	AKT	Phase 1a	Phase 1b	Solid tumors